776.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$762.18
Aprire:
$763.34
Volume 24 ore:
2.44M
Relative Volume:
0.63
Capitalizzazione di mercato:
$735.86B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
63.18
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
+0.61%
1M Prestazione:
+1.80%
6M Prestazione:
+2.98%
1 anno Prestazione:
-10.34%
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
LLY
Lilly Eli Co
|
776.44 | 692.83B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.93 | 373.35B | 90.63B | 22.66B | 18.57B | 9.35 |
![]()
ABBV
Abbvie Inc
|
187.11 | 329.24B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
116.83 | 231.66B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
NVO
Novo Nordisk Adr
|
66.78 | 298.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-05 | Downgrade | Erste Group | Buy → Hold |
2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
2024-12-10 | Ripresa | BofA Securities | Buy |
2024-11-15 | Iniziato | Wolfe Research | Outperform |
2024-10-17 | Iniziato | Bernstein | Outperform |
2024-09-13 | Ripresa | Citigroup | Buy |
2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
2024-02-16 | Reiterato | Morgan Stanley | Overweight |
2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-10-20 | Ripresa | UBS | Buy |
2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
2023-07-26 | Reiterato | Citigroup | Buy |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-05-24 | Reiterato | BofA Securities | Buy |
2023-05-24 | Reiterato | UBS | Buy |
2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | Iniziato | Jefferies | Hold |
2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
2022-11-18 | Iniziato | Credit Suisse | Outperform |
2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
2022-05-23 | Iniziato | SVB Leerink | Outperform |
2022-04-06 | Ripresa | Morgan Stanley | Overweight |
2022-03-10 | Iniziato | Daiwa Securities | Outperform |
2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
2022-01-03 | Reiterato | Bernstein | Mkt Perform |
2021-12-17 | Iniziato | Goldman | Neutral |
2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
2021-12-16 | Reiterato | BofA Securities | Buy |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
2021-07-27 | Ripresa | Truist | Buy |
2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | Ripresa | Bernstein | Mkt Perform |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-04-21 | Downgrade | UBS | Buy → Neutral |
2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | Iniziato | Mizuho | Neutral |
2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | Ripresa | BofA/Merrill | Buy |
2019-05-28 | Iniziato | Goldman | Buy |
2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
2019-03-12 | Iniziato | JP Morgan | Overweight |
2019-01-23 | Iniziato | UBS | Buy |
2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2018-10-09 | Iniziato | Guggenheim | Buy |
2018-10-01 | Reiterato | SunTrust | Buy |
2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease - GlobeNewswire Inc.
BMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
BMO Capital reiterates Eli Lilly stock rating with $900 price target By Investing.com - Investing.com South Africa
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo.co
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - The Motley Fool
Eli Lilly (LLY) at a Crossroads: Assessing the Pullback, Earnings Catalysts, and Long-Term Growth in Diabetes, Obesity, and Alzheimer's - AInvest
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo.co
Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks
Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (NYSE:LLY) Shares Could Be 38% Below Their Intrinsic Value Estimate - 富途牛牛
Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey
Eli Lilly and Company - Lifespan Research Institute
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks
Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest
Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks
Eli Lilly's stock drops 3.08% to $765.51 on July 17, down 21.29% from 52-week high. - AInvest
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance
Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN
ELI LILLY AND COMPANY (LLY) - MSN
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks
Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance
Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey
Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus
Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma
Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance
Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):